A Novel Modified-Curcumin Promotes Resolvin-Like Activity and Reduces Bone Loss in Diabetes-Induced Experimental Periodontitis

References

• Isola G, Polizzi A, Santonocito S, Alibrandi A, Williams RC. Periodontitis activates the NLRP3 inflammasome in serum and saliva. J Periodontol. 2021. doi:10.1002/JPER.21-0049
   Web of Science ®Google Scholar
• Isola G, Lo Giudice A, Polizzi A, Alibrandi A, Murabito P, Indelicato F. Identification of the different salivary Interleukin-6 profiles in patients with periodontitis: a cross-sectional study. Arch Oral Biol. 2021;122:104997. doi:10.1016/j.archoralbio.2020.104997
   PubMed Web of Science ®Google Scholar
• Iacopino AM. Periodontitis and diabetes interrelationships: role of inflammation. Ann Periodontol. 2001;6(1):125–137. doi:10.1902/annals.2001.6.1.125
   PubMedGoogle Scholar
• Kinane DF, Stathopoulou PG, Papapanou PN. Periodontal diseases. Nat Rev Dis Primers. 2017;3:17038. doi:10.1038/nrdp.2017.38
   PubMed Web of Science ®Google Scholar
• Golub LM, Payne JB, Reinhardt RA, Nieman G. Can systemic diseases co-induce (not just exacerbate) periodontitis? A hypothetical “two-hit” model. J Dent Res. 2006;85(2):102–105. doi:10.1177/154405910608500201
   PubMed Web of Science ®Google Scholar
• Ueland T, Holter JC, Holten AR, et al. Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. J Infect. 2020;81(3):e41–e43. doi:10.1016/j.jinf.2020.06.061
   PubMed Web of Science ®Google Scholar
• Abers MS, Delmonte OM, Ricotta EE, et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 2021;6:1. doi:10.1172/jci.insight.144455
   Web of Science ®Google Scholar
• Frankwich K, Tibble C, Torres-Gonzalez M, et al. Proof of Concept: matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes. J Inflamm. 2012;9(1):35. doi:10.1186/1476-9255-9-35
   Google Scholar
• Derosa G, Ferrari I, D’Angelo A, et al. Matrix metalloproteinase-2 and −9 levels in obese patients. Endothelium. 2008;15(4):219–224. doi:10.1080/10623320802228815
   PubMed Web of Science ®Google Scholar
• Saini R, Saini S, Sugandha R. Periodontal disease: the sixth complication of diabetes. J Family Community Med. 2011;18(1):31. doi:10.4103/1319-1683.78636
   PubMedGoogle Scholar
• Cairo F, Rotundo R, Frazzingaro G, Muzzi L, Pini Prato GP. Diabetes mellitus as a risk factor for periodontitis. Minerva Stomatol. 2001;50(9–10):321–330.
   PubMedGoogle Scholar
• Golub LM, Lee HM, Lehrer G, et al. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J Periodontal Res. 1983;18(5):516–526. doi:10.1111/j.1600-0765.1983.tb00388.x
   PubMed Web of Science ®Google Scholar
• Golub LM, Elburki MS, Walker C, et al. Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases. Int Dent J. 2016;66(3):127–135. doi:10.1111/idj.12221
   PubMed Web of Science ®Google Scholar
• Payne JB, Golub LM, Stoner JA, et al. The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation: a randomized, double-masked, placebo-controlled clinical trial. J Am Dent Assoc. 2011;142(3):262–273. doi:10.14219/jada.archive.2011.0165
   PubMed Web of Science ®Google Scholar
• Gu Y, Walker C, Ryan ME, Payne JB, Golub LM. Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine. J Oral Microbiol. 2012;1:4.
   Google Scholar
• Golub LM, Lee HM. Periodontal therapeutics: current host-modulation agents and future directions. Periodontol 2000. 2020;82(1):186–204. doi:10.1111/prd.12315
   PubMed Web of Science ®Google Scholar
• Serhan CN. Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators. Prostaglandins Leukot Essent Fatty Acids. 2008;79(3–5):157–163. doi:10.1016/j.plefa.2008.09.012
   PubMed Web of Science ®Google Scholar
• Van Dyke TE, Hasturk H, Kantarci A, et al. Proresolving nanomedicines activate bone regeneration in periodontitis. J Dent Res. 2015;94(1):148–156. doi:10.1177/0022034514557331
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gu Y, Lee HM, et al. Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins. Curr Med Chem. 2012;19(25):4348–4358. doi:10.2174/092986712802884295
   PubMed Web of Science ®Google Scholar
• Zhang Y, Golub LM, Johnson F, Wishnia A. pKa, zinc- and serum albumin-binding of curcumin and two novel biologically-active chemically-modified curcumins. Curr Med Chem. 2012;19(25):4367–4375. doi:10.2174/092986712802884240
   PubMed Web of Science ®Google Scholar
• Elburki MS, Rossa C, Guimaraes MR, et al. A novel chemically modified curcumin reduces severity of experimental periodontal disease in rats: initial observations. Mediators Inflamm. 2014;2014:959471. doi:10.1155/2014/959471
   PubMed Web of Science ®Google Scholar
• Deng J, Golub LM, Lee HM, et al. Chemically-Modified Curcumin 2.24: a Novel Systemic Therapy for Natural Periodontitis in Dogs. J Exp Pharmacol. 2020;12:47–60. doi:10.2147/JEP.S236792
   PubMedGoogle Scholar
• Zhang Y, McClain SA, Lee HM, et al. A Novel Chemically Modified Curcumin “Normalizes” Wound-Healing in Rats with Experimentally Induced Type I Diabetes: initial Studies. J Diabetes Res. 2016;2016:5782904. doi:10.1155/2016/5782904
   PubMed Web of Science ®Google Scholar
• Wang HH, Lee HM, Raja V, et al. Enhanced efficacy of chemically modified curcumin in experimental periodontitis: systemic implications. J Exp Pharmacol. 2019;11:1–14. doi:10.2147/JEP.S171119
   PubMedGoogle Scholar
• Katzap E, Goldstein MJ, Shah NV, et al. The chondroprotective capability of curcumin (curcuma longa) and its derivatives against IL-1β and OsM-mediated chrondrolysis. Trans Orthoped Res Soc. 2011;36(SpecialIssue 1707):59.
   Google Scholar
• Mallangada NA, Vargas JM, Thomas S, et al. A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras. Mol Carcinog. 2018;57(9):1130–1143. doi:10.1002/mc.22830
   PubMed Web of Science ®Google Scholar
• Elburki MS, Moore DD, Terezakis NG, et al. A novel chemically modified curcumin reduces inflammation-mediated connective tissue breakdown in a rat model of diabetes: periodontal and systemic effects. J Periodontal Res. 2017;52(2):186–200. doi:10.1111/jre.12381
   PubMed Web of Science ®Google Scholar
• Misharin AV, Saber R, Perlman H. Eosinophil contamination of thioglycollate-elicited peritoneal macrophage cultures skews the functional readouts of in vitro assays. J Leukoc Biol. 2012;92(2):325–331. doi:10.1189/jlb.1111560
   PubMed Web of Science ®Google Scholar
• Park CH, Abramson ZR, Taba M Jr, et al. Three-dimensional micro-computed tomographic imaging of alveolar bone in experimental bone loss or repair. J Periodontol. 2007;78(2):273–281. doi:10.1902/jop.2007.060252
   PubMed Web of Science ®Google Scholar
• Cengiz IF, Oliveira JM, Reis RL. Micro-CT - a digital 3D microstructural voyage into scaffolds: a systematic review of the reported methods and results. Biomater Res. 2018;22:26. doi:10.1186/s40824-018-0136-8
   PubMedGoogle Scholar
• Liao G, Simone J, Simon SR. Paracrine downregulation of Fc gamma RIII in human monocyte-derived macrophages induced by phagocytosis of nonopsonized particles. Blood. 1994;83(8):2294–2304. doi:10.1182/blood.V83.8.2294.2294
   PubMed Web of Science ®Google Scholar
• Nishimura F, Kono T, Fujimoto C, Iwamoto Y, Murayama Y. Negative effects of chronic inflammatory periodontal disease on diabetes mellitus. J Int Acad Periodontol. 2000;2(2):49–55.
   PubMedGoogle Scholar
• Golub LM, Ramamurthy NS, Llavaneras A, et al. A chemically modified nonantimicrobial tetracycline (CMT-8) inhibits gingival matrix metalloproteinases, periodontal breakdown, and extra-oral bone loss in ovariectomized rats. Ann N Y Acad Sci. 1999;878:290–310. doi:10.1111/j.1749-6632.1999.tb07691.x
   PubMed Web of Science ®Google Scholar
• Bartold PM, Lopez-Oliva I. Periodontitis and rheumatoid arthritis: an update 2012–2017. Periodontol. 2020;83(1):189–212. doi:10.1111/prd.12300
   Google Scholar
• Isola G, Polizzi A, Alibrandi A, Williams RC, Lo Giudice A. Analysis of galectin-3 levels as a source of coronary heart disease risk during periodontitis. J Periodontal Res. 2021;56(3):597–605. doi:10.1111/jre.12860
   PubMed Web of Science ®Google Scholar
• Williams RC. A century of progress in understanding periodontal disease. Compend Contin Educ Dent. 2002;23(5 Suppl):3–10.
   PubMedGoogle Scholar
• Preshaw PM. Host response modulation in periodontics. Periodontol 2000. 2008;48:92–110. doi:10.1111/j.1600-0757.2008.00252.x
   PubMed Web of Science ®Google Scholar
• Preshaw PM. Host modulation therapy with anti-inflammatory agents. Periodontol 2000. 2018;76(1):131–149. doi:10.1111/prd.12148
   PubMed Web of Science ®Google Scholar
• Golub LM, Ryan ME, Williams RC. Modulation of the host response in the treatment of periodontitis. Dent Today. 1998;17(10):102–106, 108–109.
   PubMedGoogle Scholar
• Elburki MS, Rossa C Jr, Guimaraes-Stabili MR, et al. A Chemically Modified Curcumin (CMC 2.24) Inhibits Nuclear Factor kappaB Activation and Inflammatory Bone Loss in Murine Models of LPS-Induced Experimental Periodontitis and Diabetes-Associated Natural Periodontitis. Inflammation. 2017;40(4):1436–1449. doi:10.1007/s10753-017-0587-4
   PubMed Web of Science ®Google Scholar
• Ratter JM, Tack CJ, Netea MG, Stienstra R. Environmental Signals Influencing Myeloid Cell Metabolism and Function in Diabetes. Trends Endocrinol Metab. 2018;29(7):468–480. doi:10.1016/j.tem.2018.04.008
   PubMed Web of Science ®Google Scholar
• Cardoso EOC, Fine N, Glogauer M, et al. The Advent of COVID-19; Periodontal Research Has Identified Therapeutic Targets for Severe Respiratory Disease; an Example of Parallel Biomedical Research Agendas. Front Dent Med. 2021;2.
   Google Scholar
• Deng J, Gu Y, Lee HM, Raja V, Johnson F, Golub LM. Novel Modified-Curcumin: resolution of Cytokines and MMPs In Cell Culture. J Dent Res. 2018;97(SpecialIssue A):0129.
   Google Scholar
• Yin Y, Chen F, Wang W, Wang H, Zhang X. Resolvin D1 inhibits inflammatory response in STZ-induced diabetic retinopathy rats: possible involvement of NLRP3 inflammasome and NF-kappaB signaling pathway. Mol Vis. 2017;23:242–250.
   PubMed Web of Science ®Google Scholar
• Gu Z, Lamont GJ, Lamont RJ, Uriarte SM, Wang H, Scott DA. Resolvin D1, resolvin D2 and maresin 1 activate the GSK3beta anti-inflammatory axis in TLR4-engaged human monocytes. Innate Immun. 2016;22(3):186–195. doi:10.1177/1753425916628618
   PubMed Web of Science ®Google Scholar
• Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002;196(8):1025–1037. doi:10.1084/jem.20020760
   PubMed Web of Science ®Google Scholar
• Serhan CN, Chiang N. Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol. 2013;13(4):632–640. doi:10.1016/j.coph.2013.05.012
   PubMed Web of Science ®Google Scholar
• Bhatt HD, McClain S, Lee HM, et al. The Maximum-Tolerated-Dose And Pharmacokinetics Of A Novel Chemically-Modified-Curcumin In Rats. J Dent Res. 2020;99(SpecialIssue A):3665.
   Google Scholar